3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Sunitinib
14
aldesleukin
10
Bevacizumab
8
pembrolizumab
7
Nivolumab
7
pazopanib
5
Axitinib
5
atezolizumab
4
Interferon-alpha
4
sintilimab
3
durvalumab
3
Sorafenib
3
Everolimus
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
toripalimab
2
sargramostim
2
olaparib
2
lenvatinib
2
fludarabine phosphate
2
camrelizumab
2
avelumab
2
Neoadjuvant Therapy
2
Laparoscopy
2
Ipilimumab
2
Interferon alpha-2
2
Immunohistochemistry
2
Immune Checkpoint Inhibitors
2
Gene Expression Profiling
2
Fluorouracil
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Renal Cell
×
Protein Subunit Vaccines
×
Clear all
NCT02429440
2017-08-17
UroRCC
University Hospital Tuebingen
Phase 1/2
Unknown
40 enrolled